Worldwide Market Reports

Female Infertility Market Is Expected to Expand at an Impressive Rate by 2027

Female Infertility Market 2019 Observational studies With Top Vendors


Seattle, WA -- (SBWIRE) -- 12/03/2019 -- Female Infertility (FI) is a complex disorder defined as the inability to conceive after at least one year of timed, unprotected intercourse. The etiology of the condition spans a wide range of disorders that can be broadly classified into the following categories: diminished ovarian reserve & ovulation disorders, endometriosis, fallopian tube abnormalities, uterine factors and unexplained infertility.
The fact that a growing number of women are postponing pregnancy until later in life when fertility has generally decreased, will translate into increased use of ART fertility treatments between 2019 and 2027.

Get a Sample PDF Report:

A limited number of established companies compete in this space, and the strategy has mainly been to create improved versions of existing drugs. As such, the drugs used to treat patients have remained largely unchanged. These include, among others, blockbuster drugs such as EMD Serono's Gonal-F (follitropin alfa), Merck & Co's Follistim (follitropin beta) and Ferring Pharmaceuticals' Menopur (menotropins) which collectively claimed over 50% of the total FI market in 2019.

Among the late stage pipeline agents, key opinion leaders (KOLs) interviewed by the author were especially enthusiastic regarding nolasiban, noting a promising future for the drug in the ART treatment setting. In 2027, this drug will be worth $320m in the US and 5EU (France, Germany, Italy, Spain and the UK). Ultimately, nolasiban will be a welcome addition to the therapeutic paradigm that will partially address the unmet need of improving embryo implantation rates during ART cycles.

Female Infertility Market Scope
Overview of Female Infertility including epidemiology, etiology and current treatment options, namely ovulation induction and ART. Topline Female Infertility market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Female Infertility therapeutics sales in the 7MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Get Discount on this Report:

Female Infertility Industry Competition
Each industry assessed in the report is studied in relation to different factors such as product and application portfolios, market share, growth potential, future plans, and recent developments. Readers will be able to gain details understanding and knowledge of the competitive landscape. Most importantly, the report sheds light on strategies that leading players are banking on to maintain their dominance in the Female Infertility market. It shows how the market competition will change in the next few years and how players are preparing themselves to stay ahead of the industry expectation.

Female Infertility Market Key Players:
Merck KGaA
Merck & Co
Ferring International
Myovant Sciences
Richter Gedeon
Teva Pharmaceutical Industries
IBSA Farmaceutici Italia
ASKA Pharmaceutical

Check the details Report